IBDEI2EW ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40914,1,3,0)
 ;;=3^Thyroiditis,Acute
 ;;^UTILITY(U,$J,358.3,40914,1,4,0)
 ;;=4^E06.0
 ;;^UTILITY(U,$J,358.3,40914,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,40915,0)
 ;;=E06.1^^159^1996^54
 ;;^UTILITY(U,$J,358.3,40915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40915,1,3,0)
 ;;=3^Thyroiditis,Subacute
 ;;^UTILITY(U,$J,358.3,40915,1,4,0)
 ;;=4^E06.1
 ;;^UTILITY(U,$J,358.3,40915,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,40916,0)
 ;;=C73.^^159^1996^37
 ;;^UTILITY(U,$J,358.3,40916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40916,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,40916,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,40916,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,40917,0)
 ;;=E10.21^^159^1996^8
 ;;^UTILITY(U,$J,358.3,40917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40917,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,40917,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,40917,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,40918,0)
 ;;=E10.9^^159^1996^12
 ;;^UTILITY(U,$J,358.3,40918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40918,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,40918,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,40918,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,40919,0)
 ;;=E11.21^^159^1996^17
 ;;^UTILITY(U,$J,358.3,40919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40919,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,40919,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,40919,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,40920,0)
 ;;=E11.39^^159^1996^18
 ;;^UTILITY(U,$J,358.3,40920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40920,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,40920,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,40920,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,40921,0)
 ;;=E11.43^^159^1996^15
 ;;^UTILITY(U,$J,358.3,40921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40921,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,40921,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,40921,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,40922,0)
 ;;=E11.59^^159^1996^13
 ;;^UTILITY(U,$J,358.3,40922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40922,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,40922,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,40922,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,40923,0)
 ;;=E11.618^^159^1996^14
 ;;^UTILITY(U,$J,358.3,40923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40923,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,40923,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,40923,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,40924,0)
 ;;=E11.621^^159^1996^16
 ;;^UTILITY(U,$J,358.3,40924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40924,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,40924,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,40924,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,40925,0)
 ;;=E11.622^^159^1996^20
 ;;^UTILITY(U,$J,358.3,40925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40925,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,40925,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,40925,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,40926,0)
 ;;=E11.65^^159^1996^19
 ;;^UTILITY(U,$J,358.3,40926,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40926,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,40926,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,40926,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,40927,0)
 ;;=E11.9^^159^1996^21
